Exhibit 10.2
AMENDMENT NO. 5 RELATING TO
SPONSORED RESEARCH AND LICENSE AGREEMENT
BETWEEN CORNERSTONE THERAPEUTICS INC., FORMERLY KNOWN AS
CRITICAL THERAPEUTICS, INC.,
AND
THE FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH
DATED JANUARY 1, 2003
THIS AMENDMENT NO. 5 is made the 3rd day of August 2010.
BETWEEN:

(1)   Cornerstone Therapeutics Inc., formerly known as Critical Therapeutics,
Inc., a Delaware corporation (“CTI”); and

(2)   The Feinstein Institute for Medical Research, a New York not-for-profit
corporation (“Feinstein”).

RECITALS:

(A)   CTI and Feinstein entered into a Sponsored Research and License Agreement,
dated January 1, 2003.

(B)   The said Sponsored Research and License Agreement was modified by that
certain Letter Agreement between CTI and Feinstein dated February 3, 2004, and
was amended by each of Amendment No. 1 dated September 18, 2006, Amendment No. 2
dated January 8, 2007, Amendment No. 3 dated June 29, 2007, that certain letter
agreement effective September 26, 2007 (the “September 2007 Letter”), and
Amendment No. 4 dated August 3, 2010. The Sponsored Research and License
Agreement as so modified and so amended is referred to herein as the “Original
Agreement.”

(C)   CTI and Feinstein have agreed to amend the Original Agreement by and upon
the terms of this Amendment No. 5.

OPERATIVE PROVISIONS:

1.   Introduction, Definitions and Interpretation

  1.1   This Amendment No. 5 is supplemental to the Original Agreement.     1.2
  In this Amendment, the expression “this Amendment No. 5” shall mean this
Amendment No. 5, including its recitals and schedules.

 

[***]   Confidential portions of the exhibit have been omitted and filed
separately with the Securities and Exchange Commission.

 

--------------------------------------------------------------------------------

 

  1.3   Except where expressly provided to the contrary in this Amendment No. 5:

  1.3.1   all capitalized terms used in this Amendment No. 5 shall have the same
meanings as are assigned thereto in the Original Agreement, as amended by this
Amendment No. 5; and     1.3.2   this Amendment No. 5 shall be interpreted in
the same manner as the Original Agreement.

  1.4   References to clauses and Articles herein are to clauses and Articles of
the Original Agreement.

2.   Amendments

NOW THEREFORE, in consideration of the mutual covenants contained in the
Original Agreement and in this Amendment No. 5 and other good and valuable
consideration, the receipt and sufficiency of which are hereby acknowledged, the
parties agree that, with effect from the Amendment No. 5 Date (as defined
below), the Original Agreement is hereby amended as follows:

  2.1   In the first paragraph under Recitals of the Original Agreement, the
reference to “Field (defined below)” shall be replaced with “field of
cholinergic anti-inflammatory pathway-based products and methods.”     2.2   In
the second paragraph under Recitals of the Original Agreement, the reference to
“Field” shall be replaced with “field of cholinergic anti-inflammatory
pathway-based products and methods.”     2.3   Article 1 of the Original
Agreement shall be amended by insertion of the following additional definition
after Article 1.2(e):         “1.2(f). “Amendment No. 5 Date” shall mean
August 3, 2010.”     2.4   Article 1.3 of the Original Agreement shall be
deleted in its entirety and replaced with the following:         “1.3. “Field”
shall mean any or all uses, except for the treatment of inflammatory disorders
with antibodies to the alpha-7 nicotinic receptor(s).”     2.5   In Article 1.7
of the Original Agreement, the reference to “Field” shall be replaced with
“field of cholinergic anti-inflammatory pathway-based products and methods.”

2

--------------------------------------------------------------------------------

 

  2.6   Schedule 1.7 to the Original Agreement shall be replaced in its entirety
by Schedule 1.7 as set forth in Exhibit A hereto and incorporated herein.    
2.7   Article 1 of the Original Agreement shall be amended by insertion of the
following additional definition after Article 1.7:         “1.7(a). “Limited
Right Patent Rights” shall mean those Feinstein Patent Rights listed on
Schedule 1.7(a) together with any continuations, continuations-in-part,
divisionals, non-provisional applications with respect thereto, patents which
are granted based on any of the aforementioned applications and any reissues,
renewals, reexaminations, substitutions or extensions thereof (or of the patents
listed on Schedule 1.7(a), if any), and any foreign counterparts to any of the
foregoing.”     2.8   Schedule 1.7(a) set forth in Exhibit B hereto and
incorporated herein shall be inserted into the Original Agreement as new
Schedule 1.7(a).     2.9   In Article 1.8 of the Original Agreement, the
reference to “Field” shall be replaced with “field of cholinergic
anti-inflammatory pathway-based products and methods.”     2.10   Article 1.11
of the Original Agreement shall be deleted in its entirety and replaced with the
following:         “1.11. “Product(s)” shall mean each product for the Field:
(1) the making, use, sale or importation of which is covered by a Feinstein
Valid Patent Claim; and/or (2) made by a process covered by a Feinstein Valid
Patent Claim; and/or (3) resulting from the use of Feinstein Technology.”    
2.11   Article 1 of the Original Agreement shall be amended by insertion of the
following additional definitions after Article 1.15:         “1.15(a).
“Targacept” shall mean Targacept, Inc., a Delaware corporation.         1.15(b).
“Targacept Sublicense Agreement” shall mean the Exclusive License Agreement
between CTI and Targacept effective on or about August 3rd, 2010.”     2.12   In
Article 2.3.2 of the Original Agreement, the reference to “Field” shall be
replaced with “field of cholinergic anti-inflammatory pathway-based products and
methods.”     2.13   The first sentence of Article 3.1 of the Original Agreement
shall be deleted and replaced with the following:

3

--------------------------------------------------------------------------------

 

      “Feinstein hereby grants to CTI and its Affiliates a perpetual and
irrevocable (subject to the terms of this Agreement), worldwide,
royalty-bearing, sole and exclusive (even as to Feinstein and its Affiliates,
subject to Article 3.3, and further subject to Article 3.2) license, with the
right to sublicense (through multiple tiers of sublicensees), under Feinstein
Patent Rights and Feinstein Technology to make, have made, use, have used, offer
for sale, sell, have sold, import, have imported and/or otherwise exploit
Product(s).”     2.14   The following shall be added to the end of Article 3.4
of the Original Agreement:         “Notwithstanding anything in this Agreement
to the contrary, for so long as the Targacept Sublicense Agreement remains in
effect, Feinstein acknowledges and agrees that, without limitation, compliance
by Targacept with Section 4.1(a) of the Targacept Sublicense Agreement shall be
conclusively deemed to constitute compliance by CTI with this Article 3.4.
Further, CTI agrees to provide to Feinstein copies of all summary written
progress reports received by CTI from Targacept pursuant to Section 4.3 of the
Targacept Sublicense Agreement, subject to Article 6.1.”     2.15   Article 5.1
of the Original Agreement shall be deleted in its entirety and replaced with the
following:         “5.1. CTI Authority. Except as provided in Articles 5.4 and
5.7, CTI shall have primary responsibility for filing, prosecuting, maintaining
and defending Feinstein Patent Rights in the United States and those other
jurisdictions worldwide as CTI may in its discretion elect to pursue from time
to time, employing patent counsel of its choice. Initially, CTI’s choice for
patent counsel is the firm of Hamilton, Brook, Smith & Reynolds, P.C., Concord,
Massachusetts, for which Feinstein grants its approval. Feinstein also grants
its approval for the firm of Womble Carlyle Sandridge & Rice, PLLC (multiple
locations). If CTI decides to retain a different or additional patent counsel in
the future to file, prosecute and/or maintain Feinstein Patent Rights, Feinstein
shall have the right to approve CTI’s selection of a different or additional
patent counsel, such approval not to be unreasonably withheld, conditioned or
delayed. Patent counsel selected by CTI shall treat Feinstein as its client (as
well as CTI) and the owner of Feinstein Patent Rights; provided that the
foregoing is not intended to limit in any respect the authority of CTI as the
responsible party for filing, prosecuting, maintaining and defending Feinstein
Patent Rights as provided in this Article 5.1.”

4

--------------------------------------------------------------------------------

 

  2.16   Article 5.3 of the Original Agreement shall be deleted in its entirety
and replaced with the following:         “5.3. Right of Feinstein to be
Informed. For work performed by patent counsel selected by CTI pursuant to
Article 5.1, such patent counsel shall keep Feinstein reasonably informed of the
status of each of the patent applications and patents in the Feinstein Patent
Rights and will consult from time to time with Feinstein concerning the
prosecution of such patent applications. Such patent counsel will provide
Feinstein in a timely manner with copies of all applications in the Feinstein
Patent Rights and any other documents with respect to Feinstein Patent Rights
filed with or received from any patent office.”     2.17   Article 5.4 of the
Original Agreement shall be deleted in its entirety and replaced with the
following:         “If CTI decides to abandon any application or patent in the
Feinstein Patent Rights, it agrees to provide Feinstein with sufficient notice
to allow Feinstein to assume filing, prosecution and/or maintenance of that
application or patent using counsel of its own choice. If CTI decides not to
pursue in Australia, Canada, China, France, Germany, Italy, Japan, Spain, the
United Kingdom or the United States counterpart filings of any application or
patent in the Feinstein Patent Rights, it agrees to provide Feinstein with
sufficient notice to allow Feinstein to pursue such counterpart filing(s) using
counsel of its own choice. If Feinstein does assume future filing, prosecution
or maintenance of such application or patent or does pursue such counterpart
filing(s), CTI shall no longer be licensed under such patent application(s)
pursuant to this Agreement.”     2.18   Article 5.5 of the Original Agreement
shall be deleted in its entirety and replaced with the following:         “5.5.
Enforcement and Defense of Feinstein Patent Rights. Subject to Articles 5.7 and
5.8, if CTI or Feinstein becomes aware of any actual or potential infringement
of Feinstein Patent Rights (including a deemed infringement under the Drug Price
Competition and Patent Term Restoration Act of 1984, as amended), it will notify
the other party and CTI and Feinstein will subsequently confer about appropriate
action against such actual or potential infringement. CTI shall have the first
right, but shall not be obligated, to enforce Feinstein Patent Rights against
such infringement, or to defend against any action or proceeding alleging
non-infringement of any Feinstein Patent Rights, or to defend against any action
or proceeding alleging invalidity or unenforceability of any

5

--------------------------------------------------------------------------------

 

      Feinstein Patent Rights (any of the foregoing, a “Patent Action”), in its
own name and under its own direction and control, or settle any such Patent
Action by sublicense or otherwise; provided that Feinstein shall have the right
to participate in such Patent Action with its own counsel at its own expense and
without reimbursement hereunder and, in such event, CTI shall provide Feinstein
with an opportunity to consult regarding such Patent Action. Feinstein (i) shall
provide full cooperation at the expense of CTI and (ii) shall join such Patent
Action if reasonably requested by CTI or required by applicable law, in which
event (clause (ii)) CTI shall also reimburse Feinstein for Feinstein’s counsel
fees and expenses. Any settlement or recovery received from any such Patent
Action shall be divided [***] percent ([***]%) to CTI and [***] percent ([***]%)
to Feinstein after CTI deducts from any such settlement or recovery its
reasonable counsel fees and out-of-pocket expenses relative to such Patent
Action, except that, to the extent CTI assigns the right to bring or defend a
Patent Action to a sublicensee (or any direct or indirect sublicensee thereof),
any settlement or recovery by such sublicensee (or direct or indirect
sublicensee thereof) shall instead be allocated between CTI and such sublicensee
as provided in the agreement between CTI and such sublicensee and that portion
of such settlement or recovery received by CTI and/or its Affiliates shall be
treated as sublicense income subject to Article 4.2.4.         If CTI decides
not to bring or defend any Patent Action, then Feinstein shall have the right to
do so; provided that CTI shall have the right to participate in such Patent
Action with its own counsel at its own expense and without reimbursement
hereunder and, in such event, Feinstein shall provide CTI with an opportunity to
consult regarding such Patent Action. Any settlement or recovery received from
any such Patent Action shall be divided [***] percent ([***]%) to Feinstein and
[***] percent ([***]%) to CTI after Feinstein deducts from any such settlement
or recovery its reasonable counsel fees and out-of-pocket expenses relative to
such Patent Action.”     2.19   Article 5 of the Original Agreement shall be
amended by insertion of the following additional Articles 5.6, 5.7, 5.8, 5.9 and
5.10:         “5.6. Patent Term Extension. CTI shall have the sole right to make
all decisions in each country or jurisdiction in the world regarding patent term
extensions for each Feinstein Patent Right (other than Limited Right Patent
Rights) and for each Product, including (i) in the United States with respect to
extensions pursuant to 35 U.S.C. §156 et. seq., (b) outside of the United States
pursuant to supplementary protection certificates and (c) anywhere in the world
with respect to any other extensions that are

 

[***]   Confidential portions of the exhibit have been omitted and filed
separately with the Securities and Exchange Commission.

6

--------------------------------------------------------------------------------

 

      now or become available in the future. Upon request by CTI, and at CTI’s
sole cost and expense, Feinstein shall timely implement, or cooperate in all
reasonable respects in the timely implementation of, CTI’s decisions under this
Article 5.6.       5.7. Limited Right Patent Rights. Notwithstanding anything in
this Article 5 to the contrary, CTI shall not have any (i) filing, prosecution,
maintenance, defense or enforcement rights with respect to Limited Right Patent
Rights or (ii) obligation to pay any patent-related or other expenses of any
kind with respect to Limited Right Patent Rights.         5.8 Limitations on
Enforcement. Notwithstanding anything in this Agreement to the contrary: (i) CTI
shall not have any right to enforce any Feinstein Patent Rights against any
third party solely for making, using or selling any antibodies to the alpha-7
nicotinic receptor(s) to treat inflammatory disorders; provided that this
Article 5.8 is not intended to limit in any respect CTI’s right to bring, defend
or settle a Patent Action pursuant to Article 5.5, even if such Patent Action
arises (via counterclaim or otherwise) out of or in connection with an action
brought by a party other than CTI to enforce any Feinstein Patent Rights (other
than an action to enforce Limited Right Patent Rights and no other Feinstein
Patent Rights) against a third party solely for making, using or selling any
antibodies to the alpha-7 nicotinic receptor(s) to treat inflammatory disorders;
and (ii) none of Feinstein, its Affiliates or any of their respective licensees
shall have any right to enforce any Feinstein Patent Rights that are not Limited
Right Patent Rights against any third party for making, using or selling any
antibody to the alpha-7 nicotinic receptor(s) to treat any inflammatory disorder
without the prior written consent of Targacept, if the Targacept Sublicense
Agreement is in effect.       5.9 Assignment of Rights to Targacept and
SetPoint. As between Feinstein and CTI, CTI shall have the right to assign any
or all of its rights and/or to delegate any or all of its obligations under this
Article 5 to Targacept or any direct or indirect sublicensee of Targacept for so
long as the Targacept Sublicense Agreement remains in effect and/or to SetPoint
Medical Corporation or any direct or indirect sublicensee of SetPoint (together,
“SetPoint”) for so long as the Exclusive License Agreement between SetPoint and
CTI, as amended (the “SetPoint License”), remains in effect; provided that, for
clarity, to the extent CTI assigns a right to Targacept or SetPoint but does not
delegate a corresponding obligation, such corresponding obligation shall not be
deemed waived by Feinstein and shall remain the obligation of CTI.

7

--------------------------------------------------------------------------------

 

    5.10. Cooperation. Without limiting any other provision of this Article 5,
each of CTI and Feinstein shall cooperate with the other party in all reasonable
respects, at the reasonable expense of such other party, in the exercise of such
other party’s rights under this Article 5.”     2.20   Article 6.1 of the
Original Agreement shall be deleted in its entirety and replaced with the
following:         “6.1. Non-Disclosure Obligations. During the Research Term
and for a period of five (5) years thereafter, both parties shall maintain in
confidence, and use only for purposes of this Agreement, confidential
information and data received from the other party. In addition, for a period
beginning on the date of the Targacept Sublicense Agreement and ending five
(5) years after its expiration or termination for any reason, Feinstein shall
maintain in confidence (i) all summary written progress reports received
pursuant to Article 3.4 and all information and documents received pursuant to
Article 5.3, in each case whether received from CTI or from Targacept and
provided that such obligation with respect to information and documents received
pursuant to Article 5.3 shall not change Feinstein’s status as the owner of the
Feinstein Patent Rights, as applicable, and (ii) the terms of the Targacept
Sublicense Agreement. Upon expiration or termination of this Agreement, all
confidential information and data, and copies thereof, will be returned to the
transmitting party by the receiving party upon request of the transmitting party
(although one copy may be retained solely for legal record keeping purposes);
provided that Feinstein shall have no such obligation with respect to
information and documents received pursuant to Article 5.3.         Feinstein
agrees that Targacept shall be a third party beneficiary of (a) the preceding
paragraph as applied to summary written progress reports received pursuant to
Article 3.4 and information and documents received pursuant to Article 5.3,
(b) clause (ii) of Article 5.8 and (c) Article 8.3, entitled to enforce the
terms thereof at law or in equity; provided that this paragraph shall not create
any implication or inference as to Targacept’s rights, if any, as to any other
provision of this Agreement.”     2.21   Article 6.5 of the Original Agreement
shall be amended by deleting the reference to “CTI” and replacing it with a
reference to “each of CTI and Targacept.”     2.22   Article 8.2 of the Original
Agreement shall be deleted in its entirety and replaced with the following:

8

--------------------------------------------------------------------------------

 

      “8.2. Termination for Cause. Upon or after a breach of any material
provision of this Agreement by a party (including non-timely payment of any
payment due to Feinstein hereunder), the non-breaching party may terminate this
Agreement by giving the breaching party thirty (30) days notice in writing
specifying the breach; provided, however, that: (a) this Agreement shall not
terminate (i) if the breaching party cures the specified breach within such
thirty (30) day period or (ii) if the specified breach is not reasonably curable
within such thirty (30) day period and the breaching party has commenced cure of
such breach within the thirty (30) day period and thereafter has proceeded
diligently to cure such breach within a reasonable time; and (b) notwithstanding
the foregoing or anything in this Agreement to the contrary, in the event CTI is
the breaching party and the Targacept Sublicense Agreement is in effect:
(i) Feinstein’s notice of termination cannot be effective if a copy thereof is
not also provided to Targacept concurrently; and (ii) upon receipt of a copy of
an effective notice of termination from Feinstein, Targacept shall thereupon
have the right in its sole discretion to cure (or commence and proceed to cure)
the breach on behalf of CTI as provided in clause (a) above. Any notice to be
provided to Targacept pursuant to this Article 8.2 shall be given as provided in
Article 10.4, with Targacept’ address being “Targacept, Inc., 200 East First
Street, Suite 300, Winston-Salem, North Carolina 27101, Attention: Vice
President, Licensing, Fax: (336-480-2285) and Attention: General Counsel, Fax:
(336-480-2103).”     2.23   Article 8.3 of the Original Agreement shall be
amended by deleting the second sentence in its entirety and replacing it with
the following:         “Moreover, the provisions of Article 6 shall survive the
expiration or termination of this Agreement, except that the obligation of
Feinstein under Section 6.1 to maintain in confidence information and documents
received pursuant to Article 5.3 shall not survive such expiration or
termination; provided that in no event shall Feinstein disclose or make
available any such information or documents in any manner that identifies, or
associates such information or documents with, Targacept or any affiliate
thereof.”     2.24   Article 10.2 of the Original Agreement shall be deleted in
its entirety and replaced with the following:         “10.2. Assignment. This
Agreement may not be assigned or otherwise transferred by either party without
the written consent of the other party; provided, however, that CTI and its
Affiliates may, without such consent, assign this Agreement and its rights and
obligations hereunder in connection with the transfer or sale of all or
substantially all of its business

9

--------------------------------------------------------------------------------

 

      relating to the Field, or in the event of its merger or consolidation, or
to Targacept if the Targacept Sublicense Agreement is then in effect. Any
purported assignment in violation of the preceding sentence shall be void.
Except with respect to an assignment or delegation pursuant to Article 5.9, any
permitted assignee shall assume all obligations of its assignor under this
Agreement. Feinstein shall have the right to sell, assign or otherwise transfer
its entire right, title and interest to the patent applications and/or patents
within Feinstein Patent Rights to a Feinstein Affiliate, provided the Affiliate
assumes all of the obligations of Feinstein hereunder. Otherwise, Feinstein
shall not sell, assign or otherwise transfer title or any portion thereof to any
patent application or patent within the Feinstein Patent Rights as long as
exclusive licenses under that patent application and/or patent are still held by
CTI without the prior written consent of CTI, which consent will not be
unreasonably withheld.”

3.   No Other Amendments; Confirmations

  3.1   Save as amended by this Amendment No. 5, the parties confirm that the
Original Agreement shall continue in full force and effect in all respects.    
3.2   As of the Amendment No. 5 Date, the Research Term has expired and is no
longer in effect.     3.3   As of the Amendment No. 5 Date, neither Feinstein
nor the Principal Investigator has any abstract, manuscript, article,
presentation or the like with respect to Sponsored Research pending, under
consideration for or proposed for publication or has any plans to prepare or
submit any such abstract, manuscript, article, presentation or the like for
publication or consideration for publication.     3.4   Feinstein shall take all
actions in the future necessary under the Patent and Trademark Law Amendments
Act of 1980, as amended, codified at 35 USC §§200-212, as amended (the Bayh-Dole
Act), as well as any regulations promulgated pursuant thereto, to secure
ownership of all Feinstein Patent Rights for Feinstein, including complying with
all reporting requirements as set forth in 37 C.F.R. 401.14 and in the funding
agreements between the U.S. government (or the National Institutes of Health)
and Feinstein.     3.5   Feinstein’s right to “proceed to commercialize such
patent applications and inventions (including by way of a license grant to a
third party),” as acknowledged and agreed by CTI in clause (ii) of the third
paragraph of the September 2007 Letter, is not intended to, and shall not be
interpreted to, include any rights with respect to Products.

10

--------------------------------------------------------------------------------

 

  3.6   To Feinstein’s current knowledge, the intellectual property licensed and
rights granted to CTI pursuant to the License Agreement between CTI and
Feinstein effective July 1, 2001, as may have been amended thereafter, do not
include any patent rights or technology necessary to develop, commercialize or
otherwise exploit any Product, except and to the extent that such Product
contains an HMG polypeptide (or a fragment thereof), or an HMG receptor (or a
fragment thereof), or an antibody (or a fragment thereof) or other biological
composition that binds to any of the foregoing. Feinstein agrees that Targacept
shall be a third party beneficiary of the representation in this paragraph,
entitled to enforce the terms thereof at law or in equity; provided that the
foregoing shall not create any implication or inference as to Targacept’s
rights, if any, as to any other provision of this Amendment No. 5.

4.   Counterparts       This Amendment No. 5 may be signed in any number of
counterparts with the same effect as if the signatures to each counterpart were
upon a single instrument, and all such counterparts together shall be deemed an
original of this Amendment No. 5.

5.   Governing Law and Jurisdiction       This Amendment No. 5 shall be governed
by and considered in accordance with the laws of the State of New York without
regard to any conflict of laws provisions thereof.

6.   Targacept Sublicense Agreement and SetPoint License Amendment

Feinstein has reviewed and has no objection to the execution and performance by
CTI of (i) the Targacept Sublicense Agreement and (ii) the Second Amendment to
Exclusive License Agreement between CTI and SetPoint Medical Corporation
effective on or about the effective date of the Targacept Sublicense Agreement.
[signature page follows]

11

--------------------------------------------------------------------------------

 

IN WITNESS WHEREOF, the parties have executed and delivered this Amendment No. 5
as of the Amendment No. 5 Date.

          CORNERSTONE THERAPEUTICS INC.
      By:   /s/ Andrew Powell         Name:   Andrew Powell        Title:  
Secretary       

          THE FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH
      By:   /s/ Kirk R. Manogue, PhD         Name:   Kirk R. Manogue, PhD       
Title:   Vice President     

12

--------------------------------------------------------------------------------

 

         

EXHIBIT A — SCHEDULE 1.7

                                                              Application
number,         CRTX Docket   Attorney Docket           filing date and        
Number   Number   Application Title   priority   Inventor(s)   Status
[***]
    [***]       [***]       [***]       [***]       [***]  
[***]
    [***]       [***]       [***]       [***]       [***]  
[***]
    [***]       [***]       [***]       [***]       [***]  
[***]
    [***]       [***]       [***]       [***]       [***]  
[***]
    [***]       [***]       [***]       [***]       [***]  
[***]
    [***]       [***]       [***]       [***]       [***]  
[***]
    [***]       [***]       [***]       [***]       [***]  
[***]
    [***]       [***]       [***]       [***]       [***]  
[***]
    [***]       [***]       [***]       [***]       [***]  
[***]
    [***]       [***]       [***]       [***]       [***]  
[***]
    [***]       [***]               [***]       [***]  
[***]
    [***]       [***]       [***]       [***]       [***]  
 
                                       
[***]
    [***]       [***]       [***]       [***]       [***]  
[***]
    [***]       [***]       [***]       [***]       [***]  
[***]
    [***]       [***]       [***]       [***]       [***]  
[***]
    [***]       [***]       [***]       [***]       [***]  
[***]
    [***]       [***]       [***]       [***]       [***]  
[***]
    [***]       [***]       [***]       [***]       [***]  
[***]
    [***]       [***]       [***]       [***]       [***]  
[***]
    [***]       [***]       [***]       [***]       [***]  
[***]
    [***]       [***]       [***]       [***]       [***]  
[***]
    [***]       [***]       [***]       [***]       [***]  

 

[***]   Confidential portions of the exhibit have been omitted and filed
separately with the Securities and Exchange Commission.

 

--------------------------------------------------------------------------------

 

                                                              Application
number,         CRTX Docket   Attorney Docket           filing date and        
Number   Number   Application Title   priority   Inventor(s)   Status
[***]
    [***]       [***]       [***]       [***]       [***]  
[***]
    [***]       [***]       [***]       [***]       [***]  
[***]
    [***]       [***]       [***]       [***]       [***]  
[***]
    [***]       [***]       [***]       [***]       [***]  
[***]
    [***]       [***]       [***]       [***]       [***]  
[***]
    [***]       [***]       [***]       [***]       [***]  
[***]
    [***]       [***]       [***]       [***]       [***]  
[***]
    [***]       [***]       [***]       [***]       [***]  
[***]
    [***]       [***]       [***]       [***]       [***]  
[***]
    [***]       [***]       [***]       [***]       [***]  
[***]
    [***]       [***]       [***]       [***]       [***]  
[***]
    [***]       [***]       [***]       [***]       [***]  
[***]
    [***]       [***]       [***]       [***]       [***]  
[***]
    [***]       [***]       [***]       [***]       [***]  
 
                                       
[***]
    [***]       [***]       [***]       [***]       [***]  
[***]
    [***]       [***]       [***]       [***]       [***]  
[***]
    [***]       [***]       [***]       [***]       [***]  
[***]
    [***]       [***]       [***]       [***]       [***]  
 
                                       
[***]
    [***]       [***]       [***]       [***]       [***]  
[***]
    [***]       [***]       [***]       [***]       [***]  
[***]
    [***]       [***]       [***]       [***]       [***]  
[***]
    [***]       [***]       [***]       [***]       [***]  
[***]
    [***]       [***]       [***]       [***]       [***]  
[***]
    [***]       [***]       [***]       [***]       [***]  
[***]
    [***]       [***]       [***]       [***]       [***]  
 
                                       
[***]
    [***]       [***]       [***]       [***]       [***]  
[***]
    [***]       [***]       [***]       [***]       [***]  

 

[***]   Confidential portions of the exhibit have been omitted and filed
separately with the Securities and Exchange Commission.

2

--------------------------------------------------------------------------------

 

                                                              Application
number,         CRTX Docket   Attorney Docket           filing date and        
Number   Number   Application Title   priority   Inventor(s)   Status
[***]
    [***]       [***]       [***]       [***]       [***]  
[***]
    [***]       [***]       [***]       [***]       [***]  
[***]
    [***]       [***]       [***]       [***]       [***]  
 
                                       
[***]
    [***]       [***]       [***]       [***]       [***]  
[***]
    [***]       [***]       [***]       [***]       [***]  
[***]
    [***]       [***]       [***]       [***]       [***]  
[***]
    [***]       [***]       [***]       [***]       [***]  
[***]
    [***]       [***]       [***]       [***]       [***]  
[***]
    [***]       [***]       [***]       [***]       [***]  
[***]
    [***]       [***]       [***]       [***]       [***]  
 
                                       
[***]
    [***]       [***]       [***]       [***]       [***]  
[***]
    [***]       [***]       [***]       [***]       [***]  
[***]
    [***]       [***]       [***]       [***]       [***]  
[***]
    [***]       [***]       [***]       [***]       [***]  
[***]
    [***]       [***]       [***]       [***]       [***]  
[***]
    [***]       [***]       [***]       [***]       [***]  
[***]
    [***]       [***]       [***]       [***]       [***]  
[***]
    [***]       [***]       [***]       [***]       [***]  
[***]
    [***]       [***]       [***]       [***]       [***]  
[***]
    [***]       [***]       [***]       [***]       [***]  
[***]
    [***]       [***]       [***]       [***]       [***]  

 

[***]   Confidential portions of the exhibit have been omitted and filed
separately with the Securities and Exchange Commission.

3

--------------------------------------------------------------------------------

 

                                                              Application
number,         CRTX Docket   Attorney Docket           filing date and        
Number   Number   Application Title   priority   Inventor(s)   Status
[***]
    [***]       [***]       [***]       [***]       [***]  
[***]
    [***]       [***]       [***]       [***]       [***]  
[***]
    [***]       [***]       [***]       [***]       [***]  
[***]
    [***]       [***]       [***]       [***]       [***]  
[***]
    [***]       [***]       [***]       [***]       [***]  
[***]
    [***]       [***]       [***]       [***]       [***]  
[***]
    [***]       [***]       [***]       [***]       [***]  
[***]
    [***]       [***]       [***]       [***]       [***]  
 
                                       
[***]
    [***]       [***]       [***]       [***]       [***]  
[***]
    [***]       [***]       [***]       [***]       [***]  
[***]
    [***]       [***]       [***]       [***]       [***]  
[***]
    [***]       [***]       [***]       [***]       [***]  
[***]
    [***]       [***]       [***]       [***]       [***]  
[***]
    [***]       [***]       [***]       [***]       [***]  
 
                                    [***]  
 
                                       
[***]
    [***]       [***]       [***]       [***]       [***]  

 

[***]   Confidential portions of the exhibit have been omitted and filed
separately with the Securities and Exchange Commission.

4

--------------------------------------------------------------------------------

 

                                                              Application
number,         CRTX Docket   Attorney Docket           filing date and        
Number   Number   Application Title   priority   Inventor(s)   Status
[***]
    [***]       [***]       [***]       [***]       [***]  
[***]
    [***]       [***]       [***]       [***]       [***]  
 
                                       
[***]
    [***]       [***]       [***]       [***]       [***]  
[***]
    [***]       [***]       [***]       [***]       [***]  
[***]
    [***]       [***]       [***]       [***]       [***]  
 
                                       
[***]
    [***]       [***]       [***]       [***]       [***]  
 
                                       

(end)
 

[***]   Confidential portions of the exhibit have been omitted and filed
separately with the Securities and Exchange Commission.

5

--------------------------------------------------------------------------------

 

EXHIBIT B — SCHEDULE 1.7(a)

                                                              Application
number,         CRTX Docket   Attorney Docket           filing date and        
Number   Number   Application Title   priority   Inventor(s)   Status
[***]
    [***]       [***]       [***]       [***]       [***]  
[***]
    [***]       [***]       [***]       [***]       [***]  
[***]
    [***]       [***]       [***]       [***]       [***]  
 
                                       
[***]
    [***]       [***]       [***]       [***]       [***]  
[***]
    [***]       [***]       [***]       [***]       [***]  
[***]
    [***]       [***]       [***]       [***]       [***]  
[***]
    [***]       [***]       [***]       [***]       [***]  
[***]
    [***]       [***]       [***]       [***]       [***]  
[***]
    [***]       [***]       [***]       [***]       [***]  
[***]
    [***]       [***]       [***]       [***]       [***]  
[***]
    [***]       [***]       [***]       [***]       [***]  
 
                                       
(end)
                                       

 

[***]   Confidential portions of the exhibit have been omitted and filed
separately with the Securities and Exchange Commission.

6